A reduction in plasma Aβ 42 /Aβ 40 is associated with an increased risk of subsequent epilepsy. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease biomarkers in the plasma of obstructive sleep apnea-hypopnea syndrome patients are higher than those in the control group, and the mechanism of action may be related to sleep disorders and night hypoxia. 3 key findings →
Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source
Improving LS7 scores might do a favor to alleviate the pathology of AD in the preclinical stage, especially among the APOE ε4 allele non-carriers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our data support the diagnostic value of L-PGDS as a CSF biomarker for iNPH and suggest a possible interaction between L-PGDS and tau protein. 2 key findings →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
This study aimed to explore the diagnostic potential of plasma MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for Alzheimer's disease (AD). 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Moreover, our results revealed associations between NfL and disease severity in FTD and between tauopathy and episodic memory and lexical-semantic impairment in prodromal-AD. 5 key findings →
Participants: 72 Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral β-amyloid (cAβ) deposition and cholinergic dysfunction have been considered as major pathological and functional hallmarks of Alzheimer's disease (AD). 1 key finding →
Participants: 407 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common age-associated dementia. 3 key findings →
Participants: 107 Evidence: low
Full summary, score breakdown and related studies → Original source
The rate of cognitive decline among patients with amnestic mild cognitive impairment (aMCI) varies, and it is thus crucial to accurately predict the probability of cognitive deterioration in patients with MCI. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma t-PrP is elevated in prion diseases regardless of aetiology. 1 key finding →
Participants: 520 Evidence: low
Full summary, score breakdown and related studies → Original source
Brazil has no national dementia strategy or established pathway for evaluation of cognitive concerns, and dementia is typically diagnosed late if at all. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Preeclampsia (PE) is the leading cause of maternal and fetal mortality globally and may trigger dementia later in life in mothers and their offspring. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our results with asymmetrical presentations extend current knowledge about this rare AD variant. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
47/100
Peripheral inflammation mechanisms involved in Alzheimer's disease (AD) have yet to be accurately characterized and the identification of blood biomarker profiles could help predict cognitive decline and optimize patient care. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Some common variants within or near the coding regions of APOE, ABCA7, A2M, and BACE1 are associated with CSF Aβ42, p-tau. or p-tau/Aβ42. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Vitamin D3 has been described to have different extraskeletal roles by acting as parahormone in obesity, diabetes, cancer, cognitive impairment, and dementia and to have important regulatory functions in innate immunity. 2 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Healthy aging is the process of preserving and enhancing one's independence, physical and mental well-being, and overall quality of life. 5 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source
47/100
The developed model based on serum biomarkers and other co-variates could reflect the AD core pathology. 2 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source
ABtest-MS accurately identified brain amyloid deposition in a population of CU individuals, supporting its implementation in AD secondary prevention trials to reduce recruitment time and costs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This demonstrates that further development of mass spectrometry assays is needed to capture the isoform complexity that exists in theses biological samples. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Based on this study, a single assay of Aβ 1-40 , Aβ 1-42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent advances in new diagnostic technologies for Alzheimer's disease have improved the speed and precision of diagnosis. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
The current study tested the accuracy of primary MRI and cerebrospinal fluid (CSF) biomarker candidates and neuropsychological tests for predicting the conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia. 1 key finding →
Participants: 81 Evidence: low
Full summary, score breakdown and related studies → Original source
Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). 2 key findings →
Participants: 52 Evidence: low
Full summary, score breakdown and related studies → Original source
This study revealed that exosomal GAP43, neurogranin, SNAP25, and synaptotagmin 1 act as effective biomarkers for prediction of AD 5 to 7 years before cognitive impairment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →